South Africa: recall of Benylin pediatric syrup from Kenvue (formerly Johnson & Johnson) – 04/15/2024 at 2:50 p.m.

(AOF) – The South African Health Products Regulatory Authority (Sahpra) announced on Saturday the recall of batches of Benylin pediatric syrup after the Nigerian National Agency for Food and Drug Administration and Control ( Nafdac) reported detecting high levels of diethylene glycol there. Benylin is marketed by Kenvue, a former division of Johnson & Johnson specializing in consumer health products, of which the group only holds 9% after the split in August 2023.


Learn more about the Pharmacy sector

Oncology, priority of pharmaceutical giants

Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.

Source link -86